August 1, 2021

Edwards Lifesciences discloses FCPA investigation

On July 30, 2021, Edwards Lifesciences Corporation, a California-based cardiac care and treatment company, disclosed in a quarterly filing with the US Securities and Exchange Commission that it had retained outside counsel and was conducting an investigation into whether “certain grants and other payments initiated by certain employees of the Company in Japan” may have violated the US Foreign Corrupt Practices Act.  In its disclosure, Edwards stated that it had voluntarily notified the SEC and the US Department of Justice of the investigation, and that at the time of its filing it was not able to predict the outcome of the investigation or its potential impact on the Company’s financial statements.  Edwards did not provide further detail. 

Form 10-Q